Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74.